Literature DB >> 2202785

Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.

C G Gottfries1.   

Abstract

The 5-hydroxytryptamine (5-HT) system in the human brain is sensitive to aging. In dementia of the Alzheimer type (AD/SDAT), there are significantly reduced concentrations of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA). 5-HT-sensitive imipramine binding is reduced by almost 50%, indicating a loss of presynaptic 5-HT terminals. There also seems to be reduced tryptophan hydroxylase activity in some brain areas. In cerebrospinal fluid (CSF) from AD/SDAT patients, the concentration of 5-HIAA is reduced, and the accumulation of 5-HIAA after probenecid loading is diminished. Biochemical findings together with structural findings in the raphe nuclei indicate that the disturbance of the 5-HT system is of the same magnitude as the disturbance of the cholinergic system. Reduced activity in the 5-HT system may be of importance for activity in the hypothalamus. There is an increased concentration of arginine vasopressin, which may explain the increased activity in the hypothalamic-pituitary-adrenal axis seen in patients with AD/SDAT. This activity is reduced when a selective 5-HT reuptake blocker is given. Pharmacological treatment with 5-HT reuptake blockers improves emotional disturbances, confusion, anxiety and depressed mood in patients with AD/SDAT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202785     DOI: 10.1007/978-3-7091-3345-3_4

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

Review 1.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

2.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

3.  Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.

Authors:  Rhonda L Nelson; Zhihong Guo; Veerendra Madala Halagappa; Michelle Pearson; Audrey J Gray; Yasuji Matsuoka; Martin Brown; Bronwen Martin; Titilola Iyun; Stuart Maudsley; Robert F Clark; Mark P Mattson
Journal:  Exp Neurol       Date:  2007-02-13       Impact factor: 5.330

4.  Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease.

Authors:  Katharina Paesler; Kan Xie; Moritz M Hettich; Magdalena E Siwek; Devon P Ryan; Susanne Schröder; Anna Papazoglou; Karl Broich; Ralf Müller; Astrid Trog; Alexander Garthe; Gerd Kempermann; Marco Weiergräber; Dan Ehninger
Journal:  Neural Plast       Date:  2015-03-26       Impact factor: 3.599

Review 5.  Pharmacological Treatment of Depression in Alzheimer's Disease: A Challenging Task.

Authors:  Tommaso Cassano; Silvio Calcagnini; Antonio Carbone; Vidyasagar Naik Bukke; Stanislaw Orkisz; Rosanna Villani; Adele Romano; Carlo Avolio; Silvana Gaetani
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.